Glecaprevir/Pibrentasvir
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-GLECAPREVIR-PIBRENTASVIR |
|---|---|
| Type | Drug |
| Aliases | G/PGLE/PIBMaviretMavyretГлекапревір/Пібрентасвір |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-EASL-HCV-2023 |
Drug Facts
| Class | Pan-genotypic direct-acting antiviral (DAA) — NS3/4A + NS5A |
|---|---|
| Mechanism | Fixed-dose combination: glecaprevir is an NS3/4A protease inhibitor, pibrentasvir is an NS5A inhibitor. Pan-genotypic activity (1-6). |
| Typical dosing | 300/120 mg PO daily × 8 weeks (treatment-naive, no cirrhosis); 12 weeks (compensated cirrhosis) |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Warnings
- Risk of HBV reactivation in HCV/HBV coinfection
Notes
Alternative pan-genotypic DAA. Shorter 8-week duration than sofosbuvir/velpatasvir for treatment-naive non-cirrhotic patients. Avoid in decompensated cirrhosis (use SOF/VEL+RBV instead).
Used By
Contraindications
CI-DECOMP-CIRRHOSIS-GLEC- CI-DECOMP-CIRRHOSIS-GLEC
Regimens
REG-DAA-GLEC-PIBR- Glecaprevir/Pibrentasvir 8 weeks (treatment-naive non-cirrhotic)